Figure 5
From: Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer
S44563 enhanced the efficacy of cisplatin-based chemo-radiotherapy in SCLC xenograft tumors. H146 (a) and H69 xenograft tumor (b) Kaplan–Meier and tumor growth volume curves after treatment with fractionated X-ray irradiation and S44563, cisplatin alone or in combination. When tumors reached the appropriate size, the mice were randomized into 10 mice per group and treated with either S44563 100 mg/kg i.p., × 5 days or X-ray irradiation 2 Gy × 4, × 1 week, cisplatin 1 mg/kg daily given twice per week for 2 weeks or their combination
